Special Offering :
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
The Europe Continuous Glucose Monitoring Systems (CGMS) Market is expected to grow at a CAGR of 28.7% from 2016 to 2022. The CGMS is a relatively more efficient monitoring and treatment system for patients suffering from diabetes. However, lack of effective reimbursement system for devices and clinicians would be a major barrier to the adoption of the devices.
The component segment of the CGMS market includes transmitters and receivers, sensors and CGMS compatible insulin pumps. Sensors market was the major segment with largest market share, with revenue of $101.3 million in 2015 and is anticipated to register a CAGR of 30.0% during the forecast period. The CGMS devices have witnessed continuous technological evolution CGMS with smartphone connectivity.
Wearable CGMS is another promising product with tremendous potential within the wearable healthcare devices. Non-invasive CGMS such as Symphony CGM System, due to its user-friendliness, extensive applications and FDA approvals for the same, have gained prominence over the years. The report highlights the adoption of Continuous Glucose Monitoring Systems in Europe.
Based on the Component, the Europe Continuous Glucose Monitoring Systems Market is segmented into Sensors, Transmitters & Receivers and Integrated Insulin pumps segment. Based on the End user, the market is bifurcated into Diagnostic centersclinics, ICUs and Home Healthcare segments. The countries included in the report are Germany, UK, France, Russia, Spain, Italy and Rest of Europe region.
Key Players profiled in the report includes Roche Diagnostics, Abbott Laboratories, Dexcom Inc., Novo Nordisk, Ypsomed AG, GlySens Incorporated, Medtronic Plc and Johnson & Johnson.